The Medical Letter on Drugs and Therapeutics
Lenalidomide (Revlimid) for Anemia of Myelodysplastic Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Lenalidomide (Revlimid – Celgene), a thalidomide analog, has been approved by the FDA for treatment of patients with transfusion-dependent anemia due to myelodysplastic syndrome (MDS) associated with a 5q deletion cytogenetic abnormality and a low or low-intermediate risk of mortality and progression to leukemia (based on the International Prognostic Scoring System).1

5q DELETION AND MDS — MDS is a heterogeneous group of malignant bone marrow disorders with a high incidence of cytogenetic abnormalities. Patients with MDS often present with cytopenias, and some progress to acute leukemia. A 5q deletion can occur in up to 30% of patients with MDS; when it is the only cytogenetic abnormality, it is associated with a more favorable prognosis.1 Azacitidine (Vidaza), a pyrimidine analog used to treat MDS, was reviewed in an earlier ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lenalidomide (Revlimid) for Anemia of Myelodysplastic Syndrome
Article code: 1232b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian